Publication
Phase 1 Dose-Escalation Study of the Rapid-Clearance Radioligand [177Lu]Lu-P17-087 in Metastatic Castration-Resistant Prostate Cancer: Dosimetry, Safety, and Preliminary Efficacy.
Ruiyue Zhao, Mingzhao Li, Jie Lv, Jing Zhang, Huizhen Zhong, Yimin Fu, Jinhui Liu, Di Gu, Guohua Zeng, Hank F Kung, Lin Zhu, Jinkun Huang, Xinlu Wang
- Source
- PubMed
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260926-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Given the rapid systemic clearance and favorable kinetic profile of the novel DOTA(GA)2-conjugated ligand [177Lu]Lu-P17-087, this phase 1 study aimed to systematically evaluate the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of escalating therapeutic activities in…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available